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Abstract 
The treatment of chronic hepatitis C (CHC) has evolved in the past 15 years and 
combination of pegylated interferon plus ribavirin is its current standard therapy. 
However, several side effects are commonly observed and frequently lead to transient or 
definitive interruption of treatment. Although sarcoidosis in its systemic or cutaneous 
form is a very rare side effect in such circumstances, some cases have been reported 
even with conventional interferon. This brief review of the literature and description of a 
case of sarcoidosis occurring in a tattoo and a scar patient’s face, during treatment with 
pegylated interferon alpha-2b plus ribavirin, is an educative report directed in special to 
dermatologists. The lesion improved after drug interruption and recurred after 
retreatment with pegylated interferon alpha-2a. We conclude that this side effect must 
call the attention of doctors to seek for the diagnosis and therapy as soon as possible in 
such circumstances. No differences were noticed neither with alpha-2a nor alpha-2b 
pegylated interferon employment. 
 
Introduction 
The treatment of chronic hepatitis C (CHC) has evolved in the last 15 years from 
monotherapy with interferon alpha (IFNalpha) to the combination treatment with  
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pegylated IFN (peg-IFN) plus ribavirin for 24–48 weeks [1, 2]. Up to now, several viral, 
host and drug-related reactions in response to IFNalpha-based therapy have been 
identified [1, 3]. Recent studies suggest that liver inflammation in CHC is controlled by 
several mechanisms, including host regulatory immune responses and viral polypeptides 
interacting with cells involved in innate and adaptive immunity [4]. It is well known that 
cutaneous side effects of treatment with IFNalpha alone or IFNalpha plus ribavirin in 
patients with CHC have been widely reported, beyond the fact that the virus itself can 
cause skin lesions. However, the cutaneous side effects during therapy of CHC are of 
inflammatory type with local erythema, edema and, much less frequently, necrosis at the 
injection skin sites. By contrast, skin side effects of such drugs have few data available in 
the literature [5], although the number of reports has been increasing in the last years, 
including cosmetic filler site injections [6–11]. 
Sarcoidosis is a multisystem granulomatous disorder of unclear etiology. There are 
almost 30 cases of IFN-induced sarcoidosis reported in the literature [12, 13]. Roughly 
one half of these patients had cutaneous findings, either alone or with systemic 
involvement. More recently there have been reported dermatological diseases in patients 
receiving the combination of IFN/ribavirin or IFN/ribavirin/amantadine for the 
treatment of CHC [12, 13]. 
Case Report 
A 44-year-old man with CHC genotype 1a and a viral load of HCV >800,000 IU/ml, A2-F1 on liver 
biopsy according to METAVIR criteria, was treated for the hepatic disease. He had a seahorse tattoo in 
left deltoid region. Peg-IFNalpha-2b 1.5 μg/kg weekly and 1,000 mg of ribavirin daily was introduced. In 
the 40th week the patient reported sudden intense pain, pruritus, erythema and skin hypertrophy in the 
left deltoid area over the seahorse tattoo and in a scar on his face (fig. 1). A skin biopsy on the scar and 
tattoo showed granulomatous dermatitis (fig. 2). All tests for fungi and mycobacterium were negative. 
Chest X-ray was normal and the level of angiotensin enzyme converter was 50 IU/ml (range 18–55 
IU/ml). Hydrocortisone butyrate 1% cream was prescribed for topical use four times daily. A moderate 
relief occurred and the treatment could be completed until the 48th week. We intend to call attention 
especially to dermatologists to the possibility of a granulomatous tattoo reaction as a side effect during 
CHC treatment with peg-IFNalpha-2b plus ribavirin. Until now, eight cases of sarcoidosis as a 
complication of IFN therapy in CHC have been reported in the English language literature [14–18]. The 
most relevant topic in this case is the occurrence of disease on a tattoo area. 
Six months later retreatment using peg-IFNalpha-2a 180 μg once a week plus ribavirin 1,000 mg 
daily was tried. In the 6th week, cutaneous symptoms relapsed in an unbearable way. The patient did 
not accept to continue therapy, since hydrocortisone cream was prescribed again but no satisfactory 
pruritus and pain improvement was noticed. A prompt regression of skin reaction occurred after 
stopping therapy. 
Discussion 
Sarcoidosis is a granulomatous disorder of unknown etiology and whose epidemiology 
suggest a genetic tendency face to infectious agents being supposed to result of immune 
system deregulation leading to non-caseating granulomas as an immune reaction to an 
unknown persistent antigenic stimulus [19]. Inflammatory mediators such as IFN and 
interleukin 2 are involved in granuloma formation. IFN has been linked to pulmonary 
macrophage activation, a characteristic feature of sarcoidosis which has been assumed an 
exaggerated T helper 1 (Th-1) immune response to a variety of exogenous antigens. It 
seems very likely that a potent immunoregulatory protein for Th-1 response such as IFN 
may induce the disease [19]. In January 2003 the eighth case of IFN-related sarcoidosis 
was reported with a review of the literature [19]. Chest X-ray revealed hilar  
Case Rep Gastroenterol 2009;3:366–371 
DOI: 10.1159/000251664 
Published online: November 21, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
368
lymphadenopathy in three patients, with reticulonodular shadows in another three, while 
the patient with only cutaneous involvement had a normal chest X-ray [19]. 
The case we report presented with cutaneous sarcoidosis during CHC therapy and 
spontaneous regression of the lesions was noted with treatment discontinuation. An 
immune cell reaction triggers a greater granulomatous reaction in such patients [12]. 
Sarcoidosis during IFN therapy may present as systemic, cutaneous or combined disease. 
The disease has already been reported in tattoos after use of IFN [20]. 
We intend to emphasize, especially to dermatologists, the risks of a granulomatous 
tattoo and other cutaneous sites during CHC treatment with peg-IFNalpha-2b plus 
ribavirin. Other similar cases have been reported in the English language literature [14–
18]. Thalidomide has been also shown to have specific activity to the inflammatory 
mediators of sarcoidosis and to be an alternative beneficial therapy [21]. 
 
 
 
 
 
Fig. 1. Sarcoid reaction in a seahorse tatoo on the deltoid skin. 
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Fig. 2. Skin biopsy (HE, 400×) with granulomatous reaction from sarcoidosis. 
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